AbbVie

Yahoo Finance • 19 hours ago

Is It Too Late to Consider AbbVie After Its Strong Multi Year Share Price Rally?

If you are wondering whether AbbVie is still attractive after its huge run, or if you are late to the party, you are in the right place to unpack what the current share price really implies. Even after a strong long-term climb, with the st... Full story

Yahoo Finance • 22 hours ago

Conflicting Guidance and Rapid Innovation Leave Physicians Seeking Clarity in Relapsed/Refractory Multiple Myeloma

EXTON, PA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- “Relapsed/Refractory Multiple Myeloma (RRMM) is difficult to manage because there’s no clear, consistent guidance – ask five academic physicians and you’ll get five different answers. It’s fru... Full story

Yahoo Finance • yesterday

AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers

Data being presented showcases AbbVie's breadth and depth of research across a range of therapeutic modalities such as T-Cell Engagers, BCL-2 Inhibitors and Antibody-Drug Conjugates for a spectrum of difficult-to-treat blood cancers NORTH... Full story

Yahoo Finance • 2 days ago

Colorectal Cancer Market Set to Expand Throughout Forecast Period (2025-2034) Driven by Increasing Screening Rates and Novel Drug Approvals | DelveInsight

LAS VEGAS, Dec. 1, 2025 /PRNewswire/ -- The colorectal cancer market is growing due to rising incidence driven by aging populations and lifestyle risk factors, which increases demand for screening and treatment. Advances in molecular diagn... Full story

Yahoo Finance • 2 days ago

Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%

Amneal Pharmaceuticals LLC Approval underscores Amneal’s advanced sterile manufacturing capabilities and expansion within complex ophthalmic therapies; Launch expected in Q1 2026 BRIDGEWATER, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Amnea... Full story

Yahoo Finance • 2 days ago

If You Invested $10K In AbbVie Stock 10 Years Ago, How Much Would You Have Now?

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. AbbVie Inc. (NYSE:ABBV) engages in the research and development, manufacture, and sale of medicines and therapies worldwide. It is set t... Full story

Yahoo Finance • 3 days ago

AbbVie (NYSE:ABBV) Will Pay A Larger Dividend Than Last Year At $1.73

AbbVie Inc.'s (NYSE:ABBV) dividend will be increasing from last year's payment of the same period to $1.73 on 17th of February. This takes the annual payment to 3.0% of the current stock price, which is about average for the industry. Tru... Full story

Yahoo Finance • 5 days ago

Assessing AbbVie’s (ABBV) Valuation: Is There More Upside After Recent Performance?

AbbVie (ABBV) shares are holding steady as investors assess the company’s ongoing performance following recent earnings. With key drugs still leading the portfolio, many are watching how AbbVie manages steady growth in a competitive sector... Full story

Yahoo Finance • 5 days ago

SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance

SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases, initially for Crohn’s disease (CD) and now for ulcerative colit... Full story

Yahoo Finance • 5 days ago

L’Agence des médicaments du Canada émet une recommandation positive pour le remboursement de SKYRIZI® (risankizumab) pour le traitement de la colite ulcéreuse, et AbbVie conclut une lettre d’intention avec l’Alliance pharmaceutique pancanadienne

SKYRIZI®, un inhibiteur de l’interleukine 23 (IL-23), a fait l’objet de deux recommandations consécutives de l’Agence des médicaments du Canada (AMC) visant son remboursement pour le traitement des maladies inflammatoires de l’intestin, in... Full story

Yahoo Finance • 7 days ago

CMS unveils price reductions for 15 drugs for 2027

[Pills and money] txking/iStock via Getty Images Individuals covered under Medicare can expect significant savings on the 15 drugs that were selected earlier this year for drug price negotiations under the Inflation Reduction Act starting... Full story

Yahoo Finance • 7 days ago

Riding the gravy train: Dividend stocks carving out 20%+ returns

[Abstract Financial Data Visualization with Digital Stock Market Graphs] AlexSecret The 2025 trading year has been largely positive for stocks, despite a November pullback that saw increased selling pressures. Major market averages remai... Full story

Yahoo Finance • 7 days ago

Gene Therapy Collaboration and Licensing Agreements Trends Analysis Report 2025 with Directory of 787 Deals Signed Since 2016 by Company A-Z, Therapy Focus and Technology Type

Dublin, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The "Gene Therapy Collaboration and Licensing Deals 2016-2025" has been added to ResearchAndMarkets.com's offering. This report contains a comprehensive listing of 787 gene therapy deals anno... Full story

Yahoo Finance • 7 days ago

Centers for Medicare & Medicaid Services Unveils $12 Billion Net Savings From Reduction in Drug Prices

The Centers for Medicare & Medicaid Services said Tuesday it expects to achieve net savings of 44%, PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 8 days ago

AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec

National competition, in collaboration with adMare BioInnovations, demonstrates AbbVie's commitment to a thriving biotech ecosystem in Quebec One biotech will receive a year of laboratory and office space including access to shared equipm... Full story

Yahoo Finance • 8 days ago

Lancement du Prix AbbVie des innovateurs en biotechnologies au Québec : AbbVie et adMare BioInnovations encouragent l’innovation dans le domaine des sciences de la vie

Le lancement d’un concours national, en collaboration avec adMare BioInnovations, illustre l’engagement d’AbbVie à favoriser le dynamisme de l’écosystème des biotechnologies au Québec.L’entreprise biotechnologique lauréate se verra offrir... Full story

Yahoo Finance • 8 days ago

As Alphabet nears $4T, here are top 10 healthcare stocks by marketcap

[Stethoscope and US dollar banknotes on chart or graph paper, Financial, account, statistics and business data medical health concept.] manassanant pamai/iStock via Getty Images Alphabet (GOOG [https://seekingalpha.com/symbol/GOOG]) (GOOG... Full story

Yahoo Finance • 9 days ago

How Recent Developments Are Shaping Analyst Views on AbbVie’s Future Edge

Analysts have recently nudged AbbVie's consensus price target upward, rising slightly from $241.29 to $243.55 as updated sentiment filters through the market. This shift reflects increased optimism driven by strong performance in key growt... Full story

Yahoo Finance • 9 days ago

Full FDA Approval of EPKINLY Combo Therapy Could Be a Game Changer for AbbVie (ABBV)

AbbVie recently received full FDA approval for EPKINLY (epcoritamab-bysp) in combination with rituximab and lenalidomide for the treatment of adults with relapsed or refractory follicular lymphoma, following robust Phase 3 results showing... Full story

Yahoo Finance • 9 days ago

Rheumatology Therapeutics Market to Hit a Valuation of US$ 38.34 Billion by 2033 | Astute Analytica

Chicago, Nov. 24, 2025 (GLOBE NEWSWIRE) -- The global rheumatology therapeutics market was valued at US$ 28.75 billion in 2024 and is expected to reach US$ 38.34 billion by 2033, witnessing a CAGR of 3.4% during the forecast period 2025-... Full story